Notizie
Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.
Farma Industria Ticino incontra i Consiglieri di Stato Christian Vitta e Raffaele De Rosa
![](https://www.farmaindustriaticino.ch/files/2019/04/helsinn-160x160.jpeg)
Verity PharmaceuticalsTM and Helsinn Therapeutics sign exclusive agreement for the promotion of Akynzeo® and Valchlor® in Puerto Rico
![](https://www.farmaindustriaticino.ch/files/2017/02/logo_helsinn-160x160.png)
Helsinn Launches Fully Integrated Targeted Therapy (FITT) Strategy and Announces Leadership and Structural Changes
![](https://www.farmaindustriaticino.ch/files/2017/02/logo_helsinn-160x160.png)
Helsinn Group Announces European Medicines Agency’s (EMA) Acceptance for review of the Marketing Authorization Application (MAA) for Infigratinib for Patients with Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 Fusions or Rearrangements
![](https://www.farmaindustriaticino.ch/files/2017/02/logo_helsinn-160x160.png)
Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQTM (infigratinib) in Canada
![](https://www.farmaindustriaticino.ch/files/2021/12/Schermata-2021-12-20-alle-12.05.09-160x160.png)
Il 3° Rapporto di Sostenibilità conferma l’impegno di IBSA per il benessere delle Persone
![](https://www.farmaindustriaticino.ch/files/2021/12/Schermata-2021-12-09-alle-09.39.25-160x160.png)
Pubblicazione BAK “L’importanza dell’industria farmaceutica per la Svizzera”
![](https://www.farmaindustriaticino.ch/files/2017/02/logo_helsinn-160x160.png)
Linkedin